BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hodos RA, Kidd BA, Shameer K, Readhead BP, Dudley JT. In silico methods for drug repurposing and pharmacology. Wiley Interdiscip Rev Syst Biol Med 2016;8:186-210. [PMID: 27080087 DOI: 10.1002/wsbm.1337] [Cited by in Crossref: 131] [Cited by in F6Publishing: 105] [Article Influence: 21.8] [Reference Citation Analysis]
Number Citing Articles
1 Zorzanelli BC, Ouverney G, Pauli FP, da Fonseca ACC, de Almeida ECP, de Carvalho DG, Possik PA, Rabelo VW, Abreu PA, Pontes B, Ferreira VF, Forezi LDSM, da Silva FC, Robbs BK. Pro-Apoptotic Antitumoral Effect of Novel Acridine-Core Naphthoquinone Compounds against Oral Squamous Cell Carcinoma. Molecules 2022;27:5148. [PMID: 36014389 DOI: 10.3390/molecules27165148] [Reference Citation Analysis]
2 Oh KK, Choi YR, Gupta H, Ganesan R, Sharma SP, Won SM, Jeong JJ, Lee SB, Cha MG, Kwon GH, Kim DJ, Suk KT. Identification of Gut Microbiome Metabolites via Network Pharmacology Analysis in Treating Alcoholic Liver Disease. Curr Issues Mol Biol 2022;44:3253-66. [PMID: 35877448 DOI: 10.3390/cimb44070224] [Reference Citation Analysis]
3 Kitsiranuwat S, Suratanee A, Plaimas K. Integration of various protein similarities using random forest technique to infer augmented drug-protein matrix for enhancing drug-disease association prediction. Sci Prog 2022;105:368504221109215. [PMID: 35801312 DOI: 10.1177/00368504221109215] [Reference Citation Analysis]
4 Lee C, Lin J, Prokop A, Gopalakrishnan V, Hanna RN, Papa E, Freeman A, Patel S, Yu W, Huhn M, Sheikh AS, Tan K, Sellman BR, Cohen T, Mangion J, Khan FM, Gusev Y, Shameer K. StarGazer: A Hybrid Intelligence Platform for Drug Target Prioritization and Digital Drug Repositioning Using Streamlit. Front Genet 2022;13:868015. [PMID: 35711912 DOI: 10.3389/fgene.2022.868015] [Reference Citation Analysis]
5 Zong N, Wen A, Moon S, Fu S, Wang L, Zhao Y, Yu Y, Huang M, Wang Y, Zheng G, Mielke MM, Cerhan JR, Liu H. Computational drug repurposing based on electronic health records: a scoping review. NPJ Digit Med 2022;5:77. [PMID: 35701544 DOI: 10.1038/s41746-022-00617-6] [Reference Citation Analysis]
6 Zong N, Li N, Wen A, Ngo V, Yu Y, Huang M, Chowdhury S, Jiang C, Fu S, Weinshilboum R, Jiang G, Hunter L, Liu H. BETA: a comprehensive benchmark for computational drug-target prediction. Brief Bioinform 2022:bbac199. [PMID: 35649342 DOI: 10.1093/bib/bbac199] [Reference Citation Analysis]
7 Zhu S, Bai Q, Li L, Xu T. Drug repositioning in drug discovery of T2DM and repositioning potential of antidiabetic agents. Computational and Structural Biotechnology Journal 2022. [DOI: 10.1016/j.csbj.2022.05.057] [Reference Citation Analysis]
8 Paci P, Fiscon G, Conte F, Wang RS, Handy DE, Farina L, Loscalzo J. Comprehensive network medicine-based drug repositioning via integration of therapeutic efficacy and side effects. NPJ Syst Biol Appl 2022;8:12. [PMID: 35443763 DOI: 10.1038/s41540-022-00221-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Bojić T, Sencanski M, Perovic V, Milicevic J, Glisic S. In Silico Screening of Natural Compounds for Candidates 5HT6 Receptor Antagonists against Alzheimer's Disease. Molecules 2022;27:2626. [PMID: 35565976 DOI: 10.3390/molecules27092626] [Reference Citation Analysis]
10 Fisher JL, Jones EF, Flanary VL, Williams AS, Ramsey EJ, Lasseigne BN. Considerations and challenges for sex-aware drug repurposing. Biol Sex Differ 2022;13:13. [PMID: 35337371 DOI: 10.1186/s13293-022-00420-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Roberti A, Chaffey LE, Greaves DR. NF-κB Signaling and Inflammation-Drug Repurposing to Treat Inflammatory Disorders? Biology (Basel) 2022;11:372. [PMID: 35336746 DOI: 10.3390/biology11030372] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
12 Oh K, Adnan M, Cho D. Drug Investigation to Dampen the Comorbidity of Rheumatoid Arthritis and Osteoporosis via Molecular Docking Test. CIMB 2022;44:1046-61. [DOI: 10.3390/cimb44030069] [Reference Citation Analysis]
13 Lakizadeh A, Babaei M. Detection of polypharmacy side effects by integrating multiple data sources and convolutional neural networks. Mol Divers 2022. [PMID: 35072838 DOI: 10.1007/s11030-022-10382-z] [Reference Citation Analysis]
14 Jain H, Bhat AR, Dalvi H, Godugu C, Singh SB, Srivastava S. Repurposing approved therapeutics for new indication: Addressing unmet needs in psoriasis treatment. Curr Res Pharmacol Drug Discov 2021;2:100041. [PMID: 34909670 DOI: 10.1016/j.crphar.2021.100041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Mule S, Singh A, Greish K, Sahebkar A, Kesharwani P, Shukla R. Drug repurposing strategies and key challenges for COVID-19 management. J Drug Target 2021;:1-17. [PMID: 34854327 DOI: 10.1080/1061186X.2021.2013852] [Reference Citation Analysis]
16 Cancela F, Rendon-Marin S, Quintero-Gil C, Houston DR, Gumbis G, Panzera Y, Pérez R, Arbiza J, Mirazo S. Modelling of Hepatitis E virus RNA-dependent RNA polymerase genotype 3 from a chronic patient and in silico interaction analysis by molecular docking with Ribavirin. J Biomol Struct Dyn 2021;:1-17. [PMID: 34861797 DOI: 10.1080/07391102.2021.2011416] [Reference Citation Analysis]
17 Choudhury M, Dhanabalan AK, Goswami N. Understanding the binding mechanism for potential inhibition of SARS-CoV-2 Mpro and exploring the modes of ACE2 inhibition by hydroxychloroquine. J Cell Biochem 2021. [PMID: 34741481 DOI: 10.1002/jcb.30174] [Reference Citation Analysis]
18 Sharma PP, Bansal M, Sethi A, Poonam, Pena L, Goel VK, Grishina M, Chaturvedi S, Kumar D, Rathi B. Computational methods directed towards drug repurposing for COVID-19: advantages and limitations. RSC Adv 2021;11:36181-98. [PMID: 35492747 DOI: 10.1039/d1ra05320e] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Wei L, Adderley J, Leroy D, Drewry DH, Wilson DW, Kaushansky A, Doerig C. Host-directed therapy, an untapped opportunity for antimalarial intervention. Cell Rep Med 2021;2:100423. [PMID: 34693368 DOI: 10.1016/j.xcrm.2021.100423] [Reference Citation Analysis]
20 Madugula SS, John L, Nagamani S, Gaur AS, Poroikov VV, Sastry GN. Molecular descriptor analysis of approved drugs using unsupervised learning for drug repurposing. Comput Biol Med 2021;138:104856. [PMID: 34555571 DOI: 10.1016/j.compbiomed.2021.104856] [Reference Citation Analysis]
21 Mathai N, Chen Y, Kirchmair J. Validation strategies for target prediction methods. Brief Bioinform 2020;21:791-802. [PMID: 31220208 DOI: 10.1093/bib/bbz026] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 18.0] [Reference Citation Analysis]
22 Battistoni A, Volpe M. Repurposing Cardio-Metabolic Drugs to Fight Covid19. High Blood Press Cardiovasc Prev 2021;28:419-23. [PMID: 34524680 DOI: 10.1007/s40292-021-00475-5] [Reference Citation Analysis]
23 Coffin AB, Boney R, Hill J, Tian C, Steyger PS. Detecting Novel Ototoxins and Potentiation of Ototoxicity by Disease Settings. Front Neurol 2021;12:725566. [PMID: 34489859 DOI: 10.3389/fneur.2021.725566] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Luo L, Qiu Q, Huang F, Liu K, Lan Y, Li X, Huang Y, Cui L, Luo H. Drug repurposing against coronavirus disease 2019 (COVID-19): A review. J Pharm Anal 2021. [PMID: 34513115 DOI: 10.1016/j.jpha.2021.09.001] [Reference Citation Analysis]
25 Oh J, Lee HH, Jeong Y, Yoon S, An HJ, Baek M, Kim DK, Lee S. Paradoxical Pro-angiogenic Effect of Low-Dose Ellipticine Identified by In Silico Drug Repurposing. Int J Mol Sci 2021;22:9067. [PMID: 34445773 DOI: 10.3390/ijms22169067] [Reference Citation Analysis]
26 Chong LC, Gandhi G, Lee JM, Yeo WWY, Choi SB. Drug Discovery of Spinal Muscular Atrophy (SMA) from the Computational Perspective: A Comprehensive Review. Int J Mol Sci 2021;22:8962. [PMID: 34445667 DOI: 10.3390/ijms22168962] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Schuler J, Falls Z, Mangione W, Hudson ML, Bruggemann L, Samudrala R. Evaluating the performance of drug-repurposing technologies. Drug Discov Today 2022;27:49-64. [PMID: 34400352 DOI: 10.1016/j.drudis.2021.08.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 7.0] [Reference Citation Analysis]
28 Mohammad Sadeghi H, Adeli I, Mousavi T, Daniali M, Nikfar S, Abdollahi M. Drug Repurposing for the Management of Depression: Where Do We Stand Currently? Life (Basel) 2021;11:774. [PMID: 34440518 DOI: 10.3390/life11080774] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 Hassanzadeganroudsari M, Ahmadi AH, Rashidi N, Hossain MK, Habib A, Apostolopoulos V. Computational Chemistry to Repurposing Drugs for the Control of COVID-19. Biologics 2021;1:111-28. [DOI: 10.3390/biologics1020007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Sadeghi SS, Keyvanpour MR. Computational Drug Repurposing: Classification of the Research Opportunities and Challenges. Curr Comput Aided Drug Des 2020;16:354-64. [PMID: 31198115 DOI: 10.2174/1573409915666190613113822] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Gao H, Ni Y, Mo X, Li D, Teng S, Huang Q, Huang S, Liu G, Zhang S, Tang Y, Lu L, Liang H. Drug repositioning based on network-specific core genes identifies potential drugs for the treatment of autism spectrum disorder in children. Comput Struct Biotechnol J 2021;19:3908-21. [PMID: 34306572 DOI: 10.1016/j.csbj.2021.06.046] [Reference Citation Analysis]
32 Vijayan K, Wei L, Glennon EKK, Mattocks C, Bourgeois N, Staker B, Kaushansky A. Host-targeted Interventions as an Exciting Opportunity to Combat Malaria. Chem Rev 2021;121:10452-68. [PMID: 34197083 DOI: 10.1021/acs.chemrev.1c00062] [Reference Citation Analysis]
33 Cakir A, Tuncer M, Taymaz-Nikerel H, Ulucan O. Side effect prediction based on drug-induced gene expression profiles and random forest with iterative feature selection. Pharmacogenomics J 2021. [PMID: 34155353 DOI: 10.1038/s41397-021-00246-4] [Reference Citation Analysis]
34 Somolinos FJ, León C, Guerrero-aspizua S. Drug Repurposing Using Biological Networks. Processes 2021;9:1057. [DOI: 10.3390/pr9061057] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
35 Mejia-Gutierrez M, Vásquez-Paz BD, Fierro L, Maza JR. In Silico Repositioning of Dopamine Modulators with Possible Application to Schizophrenia: Pharmacophore Mapping, Molecular Docking and Molecular Dynamics Analysis. ACS Omega 2021;6:14748-64. [PMID: 34151057 DOI: 10.1021/acsomega.0c05984] [Reference Citation Analysis]
36 Matorras R, Valls R, Azkargorta M, Burgos J, Rabanal A, Elortza F, Mas JM, Sardon T. Proteomics based drug repositioning applied to improve in vitro fertilization implantation: an artificial intelligence model. Syst Biol Reprod Med 2021;67:281-97. [PMID: 34126818 DOI: 10.1080/19396368.2021.1928792] [Reference Citation Analysis]
37 El Akoum M, El Achi M. Reimagining Innovation Amid the COVID-19 Pandemic: Insights From the WISH Innovation Programme. Front Public Health 2021;9:678768. [PMID: 34164373 DOI: 10.3389/fpubh.2021.678768] [Reference Citation Analysis]
38 Madanan M, Sayed BT, Mohd Zulkefli NA, Velayudhan NC. An Artificial Intelligence Approach Based on Hybrid CNN-XGB Model to Achieve High Prediction Accuracy through Feature Extraction, Classification and Regression for Enhancing Drug Discovery in Biomedicine. International Journal of Biology and Biomedical Engineering 2021;15:190-201. [DOI: 10.46300/91011.2021.15.22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Gaudelet T, Day B, Jamasb AR, Soman J, Regep C, Liu G, Hayter JBR, Vickers R, Roberts C, Tang J, Roblin D, Blundell TL, Bronstein MM, Taylor-King JP. Utilizing graph machine learning within drug discovery and development. Brief Bioinform 2021:bbab159. [PMID: 34013350 DOI: 10.1093/bib/bbab159] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 MacLean F. Knowledge graphs and their applications in drug discovery. Expert Opin Drug Discov 2021;16:1057-69. [PMID: 33843398 DOI: 10.1080/17460441.2021.1910673] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
41 Kumar N, Sarma H, Sastry GN. Repurposing of approved drug molecules for viral infectious diseases: a molecular modelling approach. J Biomol Struct Dyn 2021;:1-17. [PMID: 33810775 DOI: 10.1080/07391102.2021.1905558] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Arif A, Ansari S, Ahsan H, Mahmood R, Khan FH. An overview of Covid-19 pandemic: immunology and pharmacology. J Immunoassay Immunochem 2021;:1-20. [PMID: 33788668 DOI: 10.1080/15321819.2021.1904414] [Reference Citation Analysis]
43 Sadr AS, Eslahchi C, Ghassempour A, Kiaei M. In silico studies reveal structural deviations of mutant profilin-1 and interaction with riluzole and edaravone in amyotrophic lateral sclerosis. Sci Rep 2021;11:6849. [PMID: 33767237 DOI: 10.1038/s41598-021-86211-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Kitsiranuwat S, Suratanee A, Plaimas K. Multi-Data Aspects of Protein Similarity with a Learning Technique to Identify Drug-Disease Associations. Applied Sciences 2021;11:2914. [DOI: 10.3390/app11072914] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
45 Omokhua-Uyi AG, Van Staden J. Natural product remedies for COVID-19: A focus on safety. S Afr J Bot 2021;139:386-98. [PMID: 33753960 DOI: 10.1016/j.sajb.2021.03.012] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Sahoo BM, Ravi Kumar BVV, Sruti J, Mahapatra MK, Banik BK, Borah P. Drug Repurposing Strategy (DRS): Emerging Approach to Identify Potential Therapeutics for Treatment of Novel Coronavirus Infection. Front Mol Biosci 2021;8:628144. [PMID: 33718434 DOI: 10.3389/fmolb.2021.628144] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
47 Ramesh D, Vijayakumar BG, Kannan T. Advances in Nucleoside and Nucleotide Analogues in Tackling Human Immunodeficiency Virus and Hepatitis Virus Infections. ChemMedChem 2021;16:1403-19. [PMID: 33427377 DOI: 10.1002/cmdc.202000849] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
48 Peña‐guerrero J, Nguewa PA, García‐sosa AT. Machine learning, artificial intelligence, and data science breaking into drug design and neglected diseases. WIREs Comput Mol Sci 2021;11. [DOI: 10.1002/wcms.1513] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
49 Kawichai T, Suratanee A, Plaimas K. Meta-Path Based Gene Ontology Profiles for Predicting Drug-Disease Associations. IEEE Access 2021;9:41809-20. [DOI: 10.1109/access.2021.3065280] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Ozery-Flato M, Goldschmidt Y, Shaham O, Ravid S, Yanover C. Framework for identifying drug repurposing candidates from observational healthcare data. JAMIA Open 2020;3:536-44. [PMID: 33623890 DOI: 10.1093/jamiaopen/ooaa048] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
51 Kumar S, Jang C, Subedi L, Kim SY, Kim MH. Repurposing of FDA approved ring systems through bi-directional target-ring system dual screening. Sci Rep 2020;10:21133. [PMID: 33273509 DOI: 10.1038/s41598-020-78077-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
52 Shanmugam A, Muralidharan N, Velmurugan D, Gromiha MM. Therapeutic Targets and Computational Approaches on Drug Development for COVID-19. CTMC 2020;20:2210-20. [DOI: 10.2174/1568026620666200710105507] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
53 Shabani-mashcool S, Marashi S, Gharaghani S. NDDSA: A network- and domain-based method for predicting drug-side effect associations. Information Processing & Management 2020;57:102357. [DOI: 10.1016/j.ipm.2020.102357] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Ávalos-Moreno M, López-Tejada A, Blaya-Cánovas JL, Cara-Lupiañez FE, González-González A, Lorente JA, Sánchez-Rovira P, Granados-Principal S. Drug Repurposing for Triple-Negative Breast Cancer. J Pers Med 2020;10:E200. [PMID: 33138097 DOI: 10.3390/jpm10040200] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
55 Ghosh R, Chakraborty A, Biswas A, Chowdhuri S. Potential therapeutic use of corticosteroids as SARS CoV-2 main protease inhibitors: a computational study. J Biomol Struct Dyn 2020;:1-14. [PMID: 33094701 DOI: 10.1080/07391102.2020.1835728] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
56 Singh TU, Parida S, Lingaraju MC, Kesavan M, Kumar D, Singh RK. Drug repurposing approach to fight COVID-19. Pharmacol Rep 2020;72:1479-508. [PMID: 32889701 DOI: 10.1007/s43440-020-00155-6] [Cited by in Crossref: 87] [Cited by in F6Publishing: 73] [Article Influence: 43.5] [Reference Citation Analysis]
57 Laskar P, Yallapu MM, Chauhan SC. "Tomorrow Never Dies": Recent Advances in Diagnosis, Treatment, and Prevention Modalities against Coronavirus (COVID-19) amid Controversies. Diseases 2020;8:E30. [PMID: 32781617 DOI: 10.3390/diseases8030030] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
58 Pinto DP, Coutinho DS, Carvalho KIM, Ferrero MR, Silva LVD, Silveira GPE, Silva DMD, Araújo JFG, Silva ACA, Pereira HM, Fonseca LBD, Faria RX, Souza MVN, Silva ETD, Santos-Filho OA, Costa JCSD, Amendoeira FC, Martins MA. Pharmacological profiling of JME-173, a novel mexiletine derivative combining dual anti-inflammatory/anti-spasmodic functions and limited action in Na+ channels. Eur J Pharmacol 2020;885:173367. [PMID: 32750364 DOI: 10.1016/j.ejphar.2020.173367] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
59 Trigueiro-Louro J, Correia V, Figueiredo-Nunes I, Gíria M, Rebelo-de-Andrade H. Unlocking COVID therapeutic targets: A structure-based rationale against SARS-CoV-2, SARS-CoV and MERS-CoV Spike. Comput Struct Biotechnol J 2020;18:2117-31. [PMID: 32913581 DOI: 10.1016/j.csbj.2020.07.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
60 Napoli PE, Mangoni L, Gentile P, Braghiroli M, Fossarello M. A Panel of Broad-Spectrum Antivirals in Topical Ophthalmic Medications from the Drug Repurposing Approach during and after the Coronavirus Disease 2019 Era. J Clin Med 2020;9:E2441. [PMID: 32751615 DOI: 10.3390/jcm9082441] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
61 Nunnari G, Sanfilippo C, Castrogiovanni P, Imbesi R, Li Volti G, Barbagallo I, Musumeci G, Di Rosa M. Network perturbation analysis in human bronchial epithelial cells following SARS-CoV2 infection. Exp Cell Res 2020;395:112204. [PMID: 32735892 DOI: 10.1016/j.yexcr.2020.112204] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
62 Ahmed S, Mahtarin R, Ahmed SS, Akter S, Islam MS, Mamun AA, Islam R, Hossain MN, Ali MA, Sultana MUC, Parves MR, Ullah MO, Halim MA. Investigating the binding affinity, interaction, and structure-activity-relationship of 76 prescription antiviral drugs targeting RdRp and Mpro of SARS-CoV-2. J Biomol Struct Dyn 2020;:1-16. [PMID: 32720571 DOI: 10.1080/07391102.2020.1796804] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
63 Estrada E. COVID-19 and SARS-CoV-2. Modeling the present, looking at the future. Phys Rep 2020;869:1-51. [PMID: 32834430 DOI: 10.1016/j.physrep.2020.07.005] [Cited by in Crossref: 56] [Cited by in F6Publishing: 31] [Article Influence: 28.0] [Reference Citation Analysis]
64 Liu AC, Patel K, Vunikili RD, Johnson KW, Abdu F, Belman SK, Glicksberg BS, Tandale P, Fontanez R, Mathew OK, Kasarskis A, Mukherjee P, Subramanian L, Dudley JT, Shameer K. Sepsis in the era of data-driven medicine: personalizing risks, diagnoses, treatments and prognoses. Brief Bioinform 2020;21:1182-95. [PMID: 31190075 DOI: 10.1093/bib/bbz059] [Reference Citation Analysis]
65 Mujwar S, Deshmukh R, Harwansh RK, Gupta JK, Gour A. Drug Repurposing Approach for Developing Novel Therapy Against Mupirocin-Resistant Staphylococcus aureus. Assay Drug Dev Technol 2019;17:298-309. [PMID: 31634019 DOI: 10.1089/adt.2019.944] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
66 He B, Garmire L. Prediction of repurposed drugs for treating lung injury in COVID-19. F1000Res 2020;9:609. [PMID: 32934806 DOI: 10.12688/f1000research.23996.2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
67 Durojaiye AB, Clarke JD, Stamatiades GA, Wang C. Repurposing cefuroxime for treatment of COVID-19: a scoping review of in silico studies. J Biomol Struct Dyn 2021;39:4547-54. [PMID: 32538276 DOI: 10.1080/07391102.2020.1777904] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
68 Li B, Dai C, Wang L, Deng H, Li Y, Guan Z, Ni H. A novel drug repurposing approach for non-small cell lung cancer using deep learning. PLoS One 2020;15:e0233112. [PMID: 32525938 DOI: 10.1371/journal.pone.0233112] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
69 Wu Q, Taboureau O, Audouze K. Development of an adverse drug event network to predict drug toxicity. Curr Res Toxicol 2020;1:48-55. [PMID: 34345836 DOI: 10.1016/j.crtox.2020.06.001] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
70 Nogara PA, Orian L, Rocha JBT. The SeS/N interactions as a possible mechanism of δ-aminolevulinic acid dehydratase enzyme inhibition by organoselenium compounds: A computational study. Comput Toxicol 2020;15:100127. [PMID: 32572387 DOI: 10.1016/j.comtox.2020.100127] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
71 Zanni R, Galvez-llompart M, Garcia-domenech R, Galvez J. What place does molecular topology have in today’s drug discovery? Expert Opinion on Drug Discovery 2020;15:1133-44. [DOI: 10.1080/17460441.2020.1770223] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
72 Smith MR, Yevoo P, Sadahiro M, Readhead B, Kidd B, Dudley JT, Morishita H. Systematic Analysis of Environmental Chemicals That Dysregulate Critical Period Plasticity-Related Gene Expression Reveals Common Pathways That Mimic Immune Response to Pathogen. Neural Plast 2020;2020:1673897. [PMID: 32454811 DOI: 10.1155/2020/1673897] [Reference Citation Analysis]
73 Gysi DM, Nowick K. Construction, comparison and evolution of networks in life sciences and other disciplines. J R Soc Interface 2020;17:20190610. [PMID: 32370689 DOI: 10.1098/rsif.2019.0610] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
74 Sohraby F, Aryapour H. Rational drug repurposing for cancer by inclusion of the unbiased molecular dynamics simulation in the structure-based virtual screening approach: Challenges and breakthroughs. Semin Cancer Biol 2021;68:249-57. [PMID: 32360530 DOI: 10.1016/j.semcancer.2020.04.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
75 Muralidharan N, Sakthivel R, Velmurugan D, Gromiha MM. Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19. Journal of Biomolecular Structure and Dynamics 2021;39:2673-8. [DOI: 10.1080/07391102.2020.1752802] [Cited by in Crossref: 191] [Cited by in F6Publishing: 177] [Article Influence: 95.5] [Reference Citation Analysis]
76 Guilbert SM, Cardoso D, Lévy N, Muchir A, Nissan X. Hutchinson-Gilford progeria syndrome: Rejuvenating old drugs to fight accelerated ageing. Methods 2021;190:3-12. [PMID: 32278808 DOI: 10.1016/j.ymeth.2020.04.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
77 Uddin R, Khalil W. A comparative proteomic approach using metabolic pathways for the identification of potential drug targets against Helicobacter pylori. Genes Genomics 2020;42:519-41. [PMID: 32193857 DOI: 10.1007/s13258-020-00921-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
78 Cavalli E, Battaglia G, Basile MS, Bruno V, Petralia MC, Lombardo SD, Pennisi M, Kalfin R, Tancheva L, Fagone P, Nicoletti F, Mangano K. Exploratory Analysis of iPSCS-Derived Neuronal Cells as Predictors of Diagnosis and Treatment of Alzheimer Disease. Brain Sci 2020;10:E166. [PMID: 32183090 DOI: 10.3390/brainsci10030166] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
79 Zhang Y, Zheng Q, Zhou Y, Liu S. Repurposing Clinical Drugs as AdoMetDC Inhibitors Using the SCAR Strategy. Front Pharmacol 2020;11:248. [PMID: 32218733 DOI: 10.3389/fphar.2020.00248] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
80 Tanoli Z, Seemab U, Scherer A, Wennerberg K, Tang J, Vähä-Koskela M. Exploration of databases and methods supporting drug repurposing: a comprehensive survey. Brief Bioinform 2021;22:1656-78. [PMID: 32055842 DOI: 10.1093/bib/bbaa003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
81 Luo H, Li M, Yang M, Wu FX, Li Y, Wang J. Biomedical data and computational models for drug repositioning: a comprehensive review. Brief Bioinform 2021;22:1604-19. [PMID: 32043521 DOI: 10.1093/bib/bbz176] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
82 Réda C, Kaufmann E, Delahaye-Duriez A. Machine learning applications in drug development. Comput Struct Biotechnol J 2020;18:241-52. [PMID: 33489002 DOI: 10.1016/j.csbj.2019.12.006] [Cited by in Crossref: 40] [Cited by in F6Publishing: 20] [Article Influence: 13.3] [Reference Citation Analysis]
83 Speck-Planche A. Multi-Scale Modeling in Drug Discovery Against Infectious Diseases. Mini Rev Med Chem 2019;19:1560-3. [PMID: 31833463 DOI: 10.2174/138955751919191024110000] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
84 Moman E, Grishina MA, Potemkin VA. Nonparametric chemical descriptors for the calculation of ligand-biopolymer affinities with machine-learning scoring functions. J Comput Aided Mol Des 2019;33:943-53. [PMID: 31728812 DOI: 10.1007/s10822-019-00248-2] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
85 Karaman B, Sippl W. Computational Drug Repurposing: Current Trends. CMC 2019;26:5389-409. [DOI: 10.2174/0929867325666180530100332] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
86 Southall NT, Natarajan M, Lau LPL, Jonker AH, Deprez B, Guilliams T, Hunter L, Rademaker CM, Hivert V, Ardigò D; IRDiRC Data Mining and Repurposing Task Force. The use or generation of biomedical data and existing medicines to discover and establish new treatments for patients with rare diseases - recommendations of the IRDiRC Data Mining and Repurposing Task Force. Orphanet J Rare Dis 2019;14:225. [PMID: 31615551 DOI: 10.1186/s13023-019-1193-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
87 Zitnik M, Agrawal M, Leskovec J. Modeling polypharmacy side effects with graph convolutional networks. Bioinformatics 2018;34:i457-66. [PMID: 29949996 DOI: 10.1093/bioinformatics/bty294] [Cited by in Crossref: 236] [Cited by in F6Publishing: 125] [Article Influence: 78.7] [Reference Citation Analysis]
88 Zhang W, Voloudakis G, Rajagopal VM, Readhead B, Dudley JT, Schadt EE, Björkegren JLM, Kim Y, Fullard JF, Hoffman GE, Roussos P. Integrative transcriptome imputation reveals tissue-specific and shared biological mechanisms mediating susceptibility to complex traits. Nat Commun 2019;10:3834. [PMID: 31444360 DOI: 10.1038/s41467-019-11874-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 8.7] [Reference Citation Analysis]
89 Paranjpe MD, Taubes A, Sirota M. Insights into Computational Drug Repurposing for Neurodegenerative Disease. Trends Pharmacol Sci 2019;40:565-76. [PMID: 31326236 DOI: 10.1016/j.tips.2019.06.003] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 8.7] [Reference Citation Analysis]
90 Park K. A review of computational drug repurposing. Transl Clin Pharmacol 2019;27:59-63. [PMID: 32055582 DOI: 10.12793/tcp.2019.27.2.59] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 13.3] [Reference Citation Analysis]
91 Gachloo M, Wang Y, Xia J. A review of drug knowledge discovery using BioNLP and tensor or matrix decomposition. Genomics Inform 2019;17:e18. [PMID: 31307133 DOI: 10.5808/GI.2019.17.2.e18] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
92 Wagner JR, Churas CP, Liu S, Swift RV, Chiu M, Shao C, Feher VA, Burley SK, Gilson MK, Amaro RE. Continuous Evaluation of Ligand Protein Predictions: A Weekly Community Challenge for Drug Docking. Structure 2019;27:1326-1335.e4. [PMID: 31257108 DOI: 10.1016/j.str.2019.05.012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
93 Peyclit L, Baron SA, Rolain JM. Drug Repurposing to Fight Colistin and Carbapenem-Resistant Bacteria. Front Cell Infect Microbiol 2019;9:193. [PMID: 31245302 DOI: 10.3389/fcimb.2019.00193] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
94 Nelson W, Zitnik M, Wang B, Leskovec J, Goldenberg A, Sharan R. To Embed or Not: Network Embedding as a Paradigm in Computational Biology. Front Genet 2019;10:381. [PMID: 31118945 DOI: 10.3389/fgene.2019.00381] [Cited by in Crossref: 48] [Cited by in F6Publishing: 26] [Article Influence: 16.0] [Reference Citation Analysis]
95 Shameer K, Glicksberg BS, Hodos R, Johnson KW, Badgeley MA, Readhead B, Tomlinson MS, O'Connor T, Miotto R, Kidd BA, Chen R, Ma'ayan A, Dudley JT. Systematic analyses of drugs and disease indications in RepurposeDB reveal pharmacological, biological and epidemiological factors influencing drug repositioning. Brief Bioinform 2018;19:656-78. [PMID: 28200013 DOI: 10.1093/bib/bbw136] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 16.0] [Reference Citation Analysis]
96 Polamreddy P, Gattu N. The drug repurposing landscape from 2012 to 2017: evolution, challenges, and possible solutions. Drug Discovery Today 2019;24:789-95. [DOI: 10.1016/j.drudis.2018.11.022] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 10.0] [Reference Citation Analysis]
97 Pezzulo AA, Tudas RA, Stewart CG, Buonfiglio LGV, Lindsay BD, Taft PJ, Gansemer ND, Zabner J. HSP90 inhibitor geldanamycin reverts IL-13- and IL-17-induced airway goblet cell metaplasia. J Clin Invest 2019;129:744-58. [PMID: 30640172 DOI: 10.1172/JCI123524] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
98 Zhavoronkov A, Mamoshina P, Vanhaelen Q, Scheibye-Knudsen M, Moskalev A, Aliper A. Artificial intelligence for aging and longevity research: Recent advances and perspectives. Ageing Res Rev 2019;49:49-66. [PMID: 30472217 DOI: 10.1016/j.arr.2018.11.003] [Cited by in Crossref: 71] [Cited by in F6Publishing: 46] [Article Influence: 23.7] [Reference Citation Analysis]
99 [DOI: 10.1109/bibm.2018.8621568] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
100 Smith MR, Yevoo P, Sadahiro M, Austin C, Amarasiriwardena C, Awawda M, Arora M, Dudley JT, Morishita H. Integrative bioinformatics identifies postnatal lead (Pb) exposure disrupts developmental cortical plasticity. Sci Rep 2018;8:16388. [PMID: 30401819 DOI: 10.1038/s41598-018-34592-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
101 Hosomi K, Fujimoto M, Ushio K, Mao L, Kato J, Takada M. An integrative approach using real-world data to identify alternative therapeutic uses of existing drugs. PLoS One 2018;13:e0204648. [PMID: 30300381 DOI: 10.1371/journal.pone.0204648] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
102 Li H, Wang X, Yu H, Zhu J, Jin H, Wang A, Yang Z. Combining in vitro and in silico Approaches to Find New Candidate Drugs Targeting the Pathological Proteins Related to the Alzheimer's Disease. Curr Neuropharmacol 2018;16:758-68. [PMID: 29086699 DOI: 10.2174/1570159X15666171030142108] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
103 [DOI: 10.1109/tencon.2018.8650298] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
104 Zitnik M, Nguyen F, Wang B, Leskovec J, Goldenberg A, Hoffman MM. Machine Learning for Integrating Data in Biology and Medicine: Principles, Practice, and Opportunities. Inf Fusion 2019;50:71-91. [PMID: 30467459 DOI: 10.1016/j.inffus.2018.09.012] [Cited by in Crossref: 144] [Cited by in F6Publishing: 84] [Article Influence: 36.0] [Reference Citation Analysis]
105 Shameer K, Perez-Rodriguez MM, Bachar R, Li L, Johnson A, Johnson KW, Glicksberg BS, Smith MR, Readhead B, Scarpa J, Jebakaran J, Kovatch P, Lim S, Goodman W, Reich DL, Kasarskis A, Tatonetti NP, Dudley JT. Pharmacological risk factors associated with hospital readmission rates in a psychiatric cohort identified using prescriptome data mining. BMC Med Inform Decis Mak 2018;18:79. [PMID: 30255805 DOI: 10.1186/s12911-018-0653-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
106 Vlietstra WJ, Vos R, Sijbers AM, van Mulligen EM, Kors JA. Using predicate and provenance information from a knowledge graph for drug efficacy screening. J Biomed Semantics 2018;9:23. [PMID: 30189889 DOI: 10.1186/s13326-018-0189-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
107 Shameer K, Nayarisseri A, Romero Duran FX, Gonzalez-Diaz H. Editorial: Improving Neuropharmacology using Big Data, Machine Learning and Computational Algorithms. Curr Neuropharmacol 2017;15:1058-61. [PMID: 29199918 DOI: 10.2174/1570159X1508171114113425] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
108 Aguirre-Plans J, Piñero J, Menche J, Sanz F, Furlong LI, Schmidt HHHW, Oliva B, Guney E. Proximal Pathway Enrichment Analysis for Targeting Comorbid Diseases via Network Endopharmacology. Pharmaceuticals (Basel) 2018;11:E61. [PMID: 29932108 DOI: 10.3390/ph11030061] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
109 [DOI: 10.1145/3240925.3240961] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
110 Turanli B, Grøtli M, Boren J, Nielsen J, Uhlen M, Arga KY, Mardinoglu A. Drug Repositioning for Effective Prostate Cancer Treatment. Front Physiol 2018;9:500. [PMID: 29867548 DOI: 10.3389/fphys.2018.00500] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
111 Lu L, Yu H. DR2DI: a powerful computational tool for predicting novel drug-disease associations. J Comput Aided Mol Des 2018;32:633-42. [DOI: 10.1007/s10822-018-0117-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
112 Tan SK, Jermakowicz A, Mookhtiar AK, Nemeroff CB, Schürer SC, Ayad NG. Drug Repositioning in Glioblastoma: A Pathway Perspective. Front Pharmacol 2018;9:218. [PMID: 29615902 DOI: 10.3389/fphar.2018.00218] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 10.5] [Reference Citation Analysis]
113 Douguet D. Data Sets Representative of the Structures and Experimental Properties of FDA-Approved Drugs. ACS Med Chem Lett 2018;9:204-9. [PMID: 29541361 DOI: 10.1021/acsmedchemlett.7b00462] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
114 Mucke HAM. Drug Repositioning in the Mirror of Patenting: Surveying and Mining Uncharted Territory. Front Pharmacol 2017;8:927. [PMID: 29326592 DOI: 10.3389/fphar.2017.00927] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
115 Cheng F, Hong H, Yang S, Wei Y. Individualized network-based drug repositioning infrastructure for precision oncology in the panomics era. Brief Bioinform 2017;18:682-97. [PMID: 27296652 DOI: 10.1093/bib/bbw051] [Cited by in Crossref: 14] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
116 Guney E. Revisiting Cross-Validation of Drug Similarity Based Classifiers Using Paired Data. Genomics Comput Biol 2017;4:100047. [DOI: 10.18547/gcb.2018.vol4.iss1.e100047] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
117 Schuler J, Hudson ML, Schwartz D, Samudrala R. A Systematic Review of Computational Drug Discovery, Development, and Repurposing for Ebola Virus Disease Treatment. Molecules. 2017;22. [PMID: 29053626 DOI: 10.3390/molecules22101777] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
118 Himmelstein DS, Lizee A, Hessler C, Brueggeman L, Chen SL, Hadley D, Green A, Khankhanian P, Baranzini SE. Systematic integration of biomedical knowledge prioritizes drugs for repurposing. Elife 2017;6:e26726. [PMID: 28936969 DOI: 10.7554/eLife.26726] [Cited by in Crossref: 114] [Cited by in F6Publishing: 61] [Article Influence: 22.8] [Reference Citation Analysis]
119 Ebada ME. Drug repurposing may generate novel approaches to treating depression. Journal of Pharmacy and Pharmacology 2017;69:1428-36. [DOI: 10.1111/jphp.12815] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
120 Speck-Planche A, Dias Soeiro Cordeiro MN. Speeding up Early Drug Discovery in Antiviral Research: A Fragment-Based in Silico Approach for the Design of Virtual Anti-Hepatitis C Leads. ACS Comb Sci 2017;19:501-12. [PMID: 28437091 DOI: 10.1021/acscombsci.7b00039] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 9.4] [Reference Citation Analysis]
121 Johnson KW, Shameer K, Glicksberg BS, Readhead B, Sengupta PP, Björkegren JLM, Kovacic JC, Dudley JT. Enabling Precision Cardiology Through Multiscale Biology and Systems Medicine. JACC Basic Transl Sci 2017;2:311-27. [PMID: 30062151 DOI: 10.1016/j.jacbts.2016.11.010] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 6.4] [Reference Citation Analysis]
122 Wegner CD, Goodwin A, Cook JC, Allamneni K, Sohn J, McVean M. Why Do Promising Therapies Stall in Development and How Can We Move Them Forward? Int J Toxicol 2017;36:340-9. [PMID: 28578602 DOI: 10.1177/1091581817709773] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
123 Su EW, Sanger TM. Systematic drug repositioning through mining adverse event data in ClinicalTrials.gov. PeerJ 2017;5:e3154. [PMID: 28348935 DOI: 10.7717/peerj.3154] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
124 Soysal E, Lee HJ, Zhang Y, Huang LC, Chen X, Wei Q, Zheng W, Chang JT, Cohen T, Sun J, Xu H. CATTLE (CAncer treatment treasury with linked evidence): An integrated knowledge base for personalized oncology research and practice. CPT Pharmacometrics Syst Pharmacol 2017;6:188-96. [PMID: 28296354 DOI: 10.1002/psp4.12174] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
125 Astolfi A, Felicetti T, Iraci N, Manfroni G, Massari S, Pietrella D, Tabarrini O, Kaatz GW, Barreca ML, Sabatini S, Cecchetti V. Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA Efflux Pump Inhibitors. J Med Chem 2017;60:1598-604. [PMID: 28117588 DOI: 10.1021/acs.jmedchem.6b01439] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 6.6] [Reference Citation Analysis]
126 Smith MR, Burman P, Sadahiro M, Kidd BA, Dudley JT, Morishita H. Integrative Analysis of Disease Signatures Shows Inflammation Disrupts Juvenile Experience-Dependent Cortical Plasticity. eNeuro 2016;3:ENEURO. [PMID: 28101530 DOI: 10.1523/ENEURO.0240-16.2016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
127 Wooden B, Goossens N, Hoshida Y, Friedman SL. Using Big Data to Discover Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases. Gastroenterology 2017;152:53-67.e3. [PMID: 27773806 DOI: 10.1053/j.gastro.2016.09.065] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 5.7] [Reference Citation Analysis]
128 Vanhaelen Q, Mamoshina P, Aliper AM, Artemov A, Lezhnina K, Ozerov I, Labat I, Zhavoronkov A. Design of efficient computational workflows for in silico drug repurposing. Drug Discov Today 2017;22:210-22. [PMID: 27693712 DOI: 10.1016/j.drudis.2016.09.019] [Cited by in Crossref: 81] [Cited by in F6Publishing: 63] [Article Influence: 13.5] [Reference Citation Analysis]
129 Niehues H. [Sleep and its pharmacologic treatment]. Landarzt. 1967;43:599-604. [PMID: 5629554 DOI: 10.1186/s12918-017-0464-7] [Cited by in Crossref: 118] [Cited by in F6Publishing: 105] [Article Influence: 2.2] [Reference Citation Analysis]
130 [DOI: 10.1101/333021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
131 [DOI: 10.1101/765305] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]